Group One Trading’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-36,100
| Closed | -$146K | – | 8000 |
|
|
2025
Q1 | $146K | Sell |
36,100
-10,400
| -22% | -$34.7K | ﹤0.01% | 4276 |
|
|
2024
Q4 | $149K | Buy |
46,500
+31,400
| +208% | +$106K | ﹤0.01% | 4181 |
|
|
2024
Q3 | $33.8K | Sell |
15,100
-11,000
| -42% | -$25.4K | ﹤0.01% | 4912 |
|
|
2024
Q2 | $56.1K | Sell |
26,100
-21,700
| -45% | -$38.6K | ﹤0.01% | 4442 |
|
|
2024
Q1 | $98K | Sell |
47,800
-45,100
| -49% | -$90K | ﹤0.01% | 4180 |
|
|
2023
Q4 | $213K | Buy |
92,900
+62,600
| +207% | +$136K | ﹤0.01% | 3812 |
|
|
2023
Q3 | $51.5K | Buy |
30,300
+18,600
| +159% | +$42.3K | ﹤0.01% | 5072 |
|
|
2023
Q2 | $28.9K | Buy |
11,700
+5,200
| +80% | +$14.2K | ﹤0.01% | 5707 |
|
|
2023
Q1 | $14.6K | Sell |
6,500
-17,200
| -73% | -$86.3K | ﹤0.01% | 5722 |
|
|
2022
Q4 | $121K | Buy |
23,700
+14,360
| +154% | +$103K | ﹤0.01% | 4266 |
|
|
2022
Q3 | $97K | Sell |
9,340
-950
| -9% | -$11.3K | ﹤0.01% | 4810 |
|
|
2022
Q2 | $106K | Buy |
10,290
+3,550
| +53% | +$46.5K | ﹤0.01% | 4928 |
|
|
2022
Q1 | $119K | Buy |
6,740
+4,120
| +157% | +$88.5K | ﹤0.01% | 5321 |
|
|
2021
Q4 | $81K | Buy |
2,620
+1,780
| +212% | +$58.9K | ﹤0.01% | 5910 |
|
|
2021
Q3 | $28K | Buy |
+840
| New | +$24.8K | ﹤0.01% | 6956 |
|
Group One Trading's CKPT Position: Q2 2025 in Review
Group One Trading sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 25,632 shares — an estimated $104K sold.
Group One Trading first reported a position in CKPT in Q3 2021 and held it in 8 quarters. The position peaked at $311K in Q1 2022. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- Group One Trading reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- Group One Trading sold 25,632 Checkpoint Therapeutics shares in Q2 2025, an estimated $104K.
- Group One Trading first reported a position in Checkpoint Therapeutics in Q3 2021 and held it in 8 quarters.
- Group One Trading's Checkpoint Therapeutics position peaked at $311K in Q1 2022.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on Group One Trading's 13F filing for Q2 2025, filed 14 Aug 2025.